Monitor 2026 execution on margin improvement initiatives and remediation progress in Tissue Technologies. The stock may react to whether the company can achieve its guidance of $2.30-$2.40 adjusted EPS despite ongoing operational challenges.
Price Chart
Executive Summary
Integra LifeSciences reported mixed results for 2025, with full-year revenue up 1.5% but adjusted EPS down 12.9% YoY, driven by a $511M goodwill impairment. The company guided for 2026 revenue growth of 1.6-4.1% and adjusted EPS of $2.30-$2.40, citing margin improvement initiatives. Fourth-quarter revenue declined 1.7% with a GAAP net loss of $1.7M.
Key Financial Metrics
Key Facts
- Full-year 2025 revenue was $1.635B, up 1.5% YoY, but organic revenue declined 0.7%
- GAAP EPS was $(6.74) vs. $(0.09) in 2024, due to $511M goodwill impairment
- Adjusted EPS was $2.23, down 12.9% from $2.56 in 2024
- 2026 guidance: revenue $1.662B-$1.702B (1.6-4.1% growth), adjusted EPS $2.30-$2.40
- Tissue Technologies revenue fell 12.8% YoY in Q4 due to remediation efforts
Financial Impact
Revenue growth of 1.5% in 2025 with significant decline in profitability; $511M non-cash goodwill impairment
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Codman Specialty Surgical | $1.2B | +5.0% |
| Tissue Technologies | $434.7M | -6.9% |
Risk Factors
- Ongoing quality and supply chain challenges affecting Tissue Technologies segment
- High leverage with $1.6B net debt and 4.5x total leverage ratio
- Execution risk on transformation plan and margin improvement targets
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000917520-26-000008 |
| Document: iart-20260226.htm | 0000917520-26-000008 |
| Document: 0000917520-26-000008-index-headers.html | 0000917520-26-000008 |
| Document: 0000917520-26-000008-index.html | 0000917520-26-000008 |
| Document: 0000917520-26-000008.txt | 0000917520-26-000008 |
| CONTEXT: Previous Earnings (2026-02-26) | 0000917520-26-000008 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 8-K | $11.84 | awaiting T+5 | — | $12.13 (−2.41%) |
Oct 19, 2026 6d ago | 8-K | $13.33 | awaiting T+5 | — | $12.13 (−9.04%) |
Oct 14, 2026 12d ago | Court Ruling | $13.53 $12.33 | ▼ −8.91% | ▼ −7.89% | $12.13 (−10.38%) |
Oct 13, 2026 12d ago | 3 | $13.18 $11.84 | ▼ −10.13% | ▼ −10.59% | $12.13 (−7.97%) |
Oct 9, 2026 16d ago | 8-K | $13.98 $13.45 | ▲ +3.79% | ▲ +2.30% | $12.13 (+13.27%) |
Oct 6, 2026 20d ago | Press Release | $13.32 | awaiting T+5 | — | $12.13 (−8.97%) |
Oct 2, 2026 24d ago | 8-K | $12.68 $13.44 | ▼ −5.99% | ▼ −4.83% | $12.13 (+4.38%) |
Oct 2, 2026 24d ago | Press Release | $12.68 $13.44 | ▼ −5.99% | ▼ −4.83% | $12.13 (+4.38%) |
Sep 8, 2026 6w ago | 8-K | $16.26 $15.71 | ▼ −3.38% | ▼ −2.72% | $12.13 (−25.43%) |
May 8, 2026 24w ago | 8-K | $13.97 $14.11 | ▲ +1.00% | ▲ +1.09% | $12.13 (−13.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers